Ultragenyx Pharmaceutical
RARE
RARE
226 hedge funds and large institutions have $3.14B invested in Ultragenyx Pharmaceutical in 2022 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 103 increasing their positions, 60 reducing their positions, and 40 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
0.09% more ownership
Funds ownership: 96.91% → 97.01% (+0.09%)
3% less funds holding
Funds holding: 232 → 226 (-6)
13% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 40
Holders
226
Holding in Top 10
3
Calls
$18.3M
Puts
$16M
Top Buyers
| 1 | +$63.2M | |
| 2 | +$36.9M | |
| 3 | +$28.6M | |
| 4 |
Millennium Management
New York
|
+$18.8M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$18.1M |
Top Sellers
| 1 | -$86.7M | |
| 2 | -$82.5M | |
| 3 | -$33.2M | |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$28.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$26M |